As healthcare grapples with a wide array of challenges that pose a threat to the industry's future improving children's health looms as a potential answer to drive sustainability for the system.At Nemours Children's Health is focused on advocating for the value of investing in childhood prevention while strategizing for where children's health is heading The United States has a massive burden of chronic disease, one that could be significantly lessened by addressing health trajectories in children, according to Moss. That burden is creating problems in several areas, from the $4.5 trillion in annual costs to the strain on providers' resources to care for patients "The biggest issue for me continues to be our opportunity to do a better job demonstrating that children's health is not just about treating sick kids," Moss told HealthLeaders "Children's health is about the health of our entire country "One of the things that that I always try to do that I think the whole children's hospital industry can do a better job of is demonstrating that children's health is the lever we have to power our society and our economy I just get out of bed every day thinking about that because if we could do a better job of that the shiny object challenges of the day would tend to fade away." the priority is advancing whole child health models that promote health and wellbeing over the course of a child's life Those models are influencing how children's health is trending and the type of medical care children's hospitals are emphasizing.With higher acuity in inpatient settings and more care being administered at home and in outpatient settings Moss believes the children's hospital of the future will be a giant ICU with only acute care beds most of the care that is delivered in the medical-surgical unit today will be delivered at home we're investing very heavily in something that we call advanced pediatric care at home which is essentially hospital-level care at home which we are actively testing and moving very rapidly towards becoming a part of the way that we deliver care here," Moss said "I hope that we're able to demonstrate to other children's health systems around the country that that's the way to go." FAAP, president and CEO, Nemours Children's Health Moss is also bullish on new technology allowing for more innovation in children's health By leveraging AI to improve care management and care coordination at a sophisticated level children's hospitals can scale a major hurdle that currently places limitations on providers."In the children's healthcare world our biggest challenge is the subset of kids we call children with medical complexity," Moss said "Those are the kids with multiple congenital anomalies the kind of things that that require what only a children's hospital can do Yet coordinating that care requires multiple specialists in a variety of procedures and it's the thing we do poorly in healthcare Nemours is partnering with a startup company that's looking at ways to create a virtual care coordinator and care manager to give the health system "essentially an unlimited workforce of roles that are really That partnership has yet to be officially announced but Moss is excited by the opportunity and expects it to greatly benefit children's families Nemours has been active with capital investments in its home states of Delaware and Florida to strengthen care delivery efforts While Nemours is interested in delivering population health and elevating children's health outside the hospital it also wants to care for the sickest of kids "An emphasis on health outside of the hospital and keeping kids out of the hospital is not a de-emphasis on high-end tertiary quaternary care for kids who need that," Moss said the health system announced it would spend $130 million in 2025 on projects in Delaware including a new Maternal and Fetal Health Program and expansion of its neonatology cancer and cardiology programs.At its Central Florida campus Nemours is investing $300 million over the next four years on expanding the pediatric hospital and building a new administrative building "We're finding with the increased visibility we've had in the market and with how responsive communities and families have been through our whole child health model we've seen a big increase in demand for our high-end tertiary quaternary services so more kids who maybe were going somewhere else are now coming to us for those services and we need to be there to deliver," Moss said Taking care of the sick will always be a core function of hospitals but bettering the health of communities in a meaningful way requires a comprehensive approach "Whether we're leaders in healthcare or we're at the front lines taking care of patients Jay Asser is the CEO editor for HealthLeaders.  Investing in children's health can reduce chronic disease and healthcare spending says Nemours Children's Health president and CEO R Nemours is working to advance hospital-level pediatric care at home and develop AI-driven care coordination even as the focus shifts to whole child health and preventive models Is the APP the answer to the CMO's workforce and budget challenges a growing tension is becoming clear: the reality of what AI can deliver versus what it can't Please enable JS and disable any ad blocker according to the company in its most recent 13F filing with the SEC The fund owned 5,012 shares of the basic materials company's stock after purchasing an additional 822 shares during the quarter Brighton Jones LLC's holdings in DuPont de Nemours were worth $382,000 as of its most recent SEC filing Institutional investors and hedge funds own 73.96% of the company's stock Wall Street Analysts Forecast GrowthSeveral brokerages have commented on DD Mizuho dropped their price target on DuPont de Nemours from $100.00 to $80.00 and set an "outperform" rating on the stock in a research report on Tuesday KeyCorp raised shares of DuPont de Nemours from a "sector weight" rating to an "overweight" rating and set a $81.00 target price on the stock in a research report on Monday UBS Group reduced their price target on shares of DuPont de Nemours from $103.00 to $75.00 and set a "buy" rating for the company in a report on Tuesday Citigroup dropped their price objective on shares of DuPont de Nemours from $95.00 to $74.00 and set a "buy" rating on the stock in a report on Tuesday reduced their target price on shares of DuPont de Nemours from $101.00 to $76.00 and set an "overweight" rating for the company in a research note on Tuesday Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock DuPont de Nemours has an average rating of "Moderate Buy" and a consensus target price of $85.79 This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting This story was reviewed by MarketBeat's editorial team prior to publication Please send any questions or comments about this story to contact@marketbeat.com MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on.. While DuPont de Nemours currently has a Moderate Buy rating among analysts top-rated analysts believe these five stocks are better buys View The Five Stocks Here Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report Explore why gold remains the ultimate investment for safeguarding wealth against inflation Whether you're planning for future generations or seeking a reliable asset in turbulent times this report is your essential guide to making informed decisions Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools In a recent report dated May 5, 2025, analyst Aleksey Yefremov from Keybanc has raised the price target for DuPont de Nemours (DD, Financial) reflecting a positive outlook on the stock's performance The investment firm has adjusted its price target from $81.00 to $85.00 Despite the revised price target, Keybanc has maintained its "Overweight" rating on DuPont de Nemours (DD, Financial) The continuation of this rating suggests confidence in the company's future prospects The increase in the price target indicates Keybanc's expectation of potential upside in DuPont de Nemours' stock (DD, Financial) valuation adding to investor insights as they consider their investment strategies Based on the consensus recommendation from 19 brokerage firms, DuPont de Nemours Inc's (DD, Financial) average brokerage recommendation is currently 2.1 Nemours Children’s Health becomes the official Children’s Health Partner of the Philadelphia Union Subaru Park and WSFS Bank Sportsplex; Proud Entitlement Partner of Kids Night this Saturday Philadelphia Union announced today that they have entered a five-year partnership with Nemours Children’s Health as it becomes the Official Children's Health Partner of the Philadelphia Union Nemours Children’s will provide on-call sports medicine care and annual physicals to the Philadelphia Union Academy throughout the duration of the partnership the Union and Nemours hosted a pep rally at their Wilmington The event included patients and their families enjoying Union carnival-style games and prizes Nathan Harriel and Jeremy Rafanello alongside mascot took a trip around the hospital and visited with patients in the physical therapy gym and orthopedics wing Union’s Chief Revenue Officer Charlie Slonaker and Nathan Harriel alongside Chief of Orthopedics for Nemours Children’s Hospital were also on-site to speak in honor of this new partnership “We are excited to announce our new partnership with Nemours Children’s Health,” said Chief Revenue Officer Charlie Slonaker “The Union and Nemours share a commitment to helping our young athletes and those in the community grow into strong We’re proud to collaborate with a partner that shares our long-term vision for youth development and community impact.” “While this partnership makes Nemours the medical care team for the Philadelphia Union Academy it also allows us to work with a well-respected team that understands the power of creating the healthiest generations of children” said Dr Chair of Orthopedics for Nemours Children’s Hospital Delaware Valley “We look forward to working with the Union to celebrate the joy of soccer with families and connect with the community.” In addition to providing on call health care to the Philadelphia Union Academy Nemours also becomes the proud entitlement partner of the Union’s Kids Night on April 26 when the club hosts D.C Nemours will also sponsor ‘Ball Delivery Kid of the Match’ which will feature a Nemours patient at each Union home game where the child will deliver the match ball and enjoy the game field side with their family Nemours will also be the supporting partner of Army Navy Cup and Eastern Pennsylvania Youth Soccer Association (EPYSA) and an associate partner of Fearless 43 Kick Childhood Cancer supporting all ‘Union Kick Childhood Cancer’ activations throughout September The 2025 schedule has been released and now is the perfect time to lock in the best seats for all the key matchups at Subaru Park Monday - Friday 9am-12pm / 2pm-6pm GMT + 1 All financial news and data tailored to specific country editions Please try using other words for your search or explore other sections of the website for relevant information Our team is working diligently to resolve the issue Thank you for your patience and understanding DuPont de Nemours (NYSE:DD) is gearing up to announce its quarterly earnings on Friday Here's a quick overview of what investors should know before the release Analysts are estimating that DuPont de Nemours will report an earnings per share (EPS) of $0.95 The market awaits DuPont de Nemours's announcement with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter It's important for new investors to understand that guidance can be a significant driver of stock prices The company's EPS beat by $0.15 in the last quarter leading to a 0.34% increase in the share price on the following day Here's a look at DuPont de Nemours's past performance and the resulting price change: Shares of DuPont de Nemours were trading at $65.99 as of April 30 Given that these returns are generally negative long-term shareholders are likely bearish going into this earnings release staying informed about market sentiments and expectations in the industry is paramount This analysis provides an exploration of the latest insights on DuPont de Nemours A total of 14 analyst ratings have been received for DuPont de Nemours with the consensus rating being Outperform The average one-year price target stands at $86.36 we explore the analyst ratings and average 1-year price targets of PPG Indus offering insights into their relative performance expectations and market positioning The peer analysis summary provides a snapshot of key metrics for PPG Indus illuminating their respective standings within the industry These metrics offer valuable insights into their market positions and comparative performance DuPont de Nemours has the highest revenue growth among its peers DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations Its portfolio includes specialty chemicals and downstream products that serve the electronics DuPont plans to spin off its electronics business by the end of 2025 Market Capitalization: Positioned above industry average the company's market capitalization underscores its superiority in size DuPont de Nemours showcased positive performance achieving a revenue growth rate of 6.69% as of 31 December This reflects a substantial increase in the company's top-line earnings the company stands out with a growth rate higher than the average among peers in the Materials sector Net Margin: DuPont de Nemours's net margin is below industry averages indicating potential challenges in maintaining strong profitability the company may face hurdles in effective cost management Return on Equity (ROE): DuPont de Nemours's ROE is below industry standards pointing towards difficulties in efficiently utilizing equity capital the company may encounter challenges in delivering satisfactory returns for shareholders Return on Assets (ROA): DuPont de Nemours's ROA is below industry averages indicating potential challenges in efficiently utilizing assets the company may face hurdles in achieving optimal financial returns Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms To track all earnings releases for DuPont de Nemours visit their earnings calendar on our site. This article was generated by Benzinga's automated content engine and reviewed by an editor Benzinga does not provide investment advice The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq This data feed is not available at this time These symbols will be available throughout the site during your session These instruments will be available throughout the site during your session Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use The firm had revenue of $3.07 billion for the quarter compared to the consensus estimate of $3.05 billion DuPont de Nemours had a return on equity of 7.12% and a net margin of 5.47% The company's revenue for the quarter was up 4.6% compared to the same quarter last year During the same quarter in the previous year DuPont de Nemours updated its FY 2025 guidance to 4.300-4.400 EPS and its Q2 2025 guidance to 1.050-1.050 EPS NYSE DD traded down $1.83 during trading on Monday 3,161,242 shares of the company's stock traded hands compared to its average volume of 2,417,504 DuPont de Nemours has a 12-month low of $53.77 and a 12-month high of $90.06 The company has a debt-to-equity ratio of 0.22 a current ratio of 1.33 and a quick ratio of 0.88 The firm has a market cap of $27.38 billion a price-to-earnings-growth ratio of 2.15 and a beta of 1.07 The company's 50 day simple moving average is $69.49 and its two-hundred day simple moving average is $76.46 The firm also recently disclosed a quarterly dividend This represents a $1.64 dividend on an annualized basis and a yield of 2.51% The ex-dividend date of this dividend is Friday DuPont de Nemours's dividend payout ratio (DPR) is presently -863.16% An institutional investor recently raised its position in DuPont de Nemours stock. Brighton Jones LLC boosted its stake in shares of DuPont de Nemours, Inc. (NYSE:DD - Free Report) by 19.6% in the fourth quarter according to the company in its most recent Form 13F filing with the Securities & Exchange Commission The firm owned 5,012 shares of the basic materials company's stock after buying an additional 822 shares during the period Brighton Jones LLC's holdings in DuPont de Nemours were worth $382,000 as of its most recent filing with the Securities & Exchange Commission 73.96% of the stock is currently owned by institutional investors BMO Capital Markets upped their target price on DuPont de Nemours from $105.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday Wolfe Research upgraded DuPont de Nemours from a "peer perform" rating to an "outperform" rating and set a $91.00 price target on the stock in a report on Friday Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock the stock presently has an average rating of "Moderate Buy" and an average target price of $85.07 Check Out Our Latest Stock Report on DD Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment DuPont de Nemours (DD, Financial) has recently been the subject of an analyst action from Morgan Stanley According to the latest report dated May 5 analyst Vincent Andrews has maintained the current rating of 'Equal-Weight' for the stock However, there has been a notable adjustment in the price target for DuPont de Nemours (DD, Financial) The price target has been lowered from USD 94.00 to USD 80.00 This adjustment represents a percentage change of -14.89% from the prior target The unchanged rating of 'Equal-Weight' indicates Morgan Stanley's perspective that the stock will perform in line with the average market performance Should you invest in DuPont de Nemours Inc (DD, Financial) right now? Before you do it, it’s important to understand the business profitability and stock valuations, and find out what the warning signs are about. See the in-depth DuPont de Nemours Inc (DD) stock research here DDDupont De Nemours Inc DD reported quarterly adjusted earnings of $1.03​​ per share for the quarter ended March 31 The mean expectation of seventeen analysts for the quarter was for earnings of 95 cents per share Wall Street expected results to range from 93 cents to 97 cents per share Revenue rose 4.6% to $3.07 billion from a year ago; analysts expected $3.04 billion Dupont De Nemours Inc's reported EPS for the quarter was a loss of $1.33​ The company reported a quarterly loss of $555 million Dupont De Nemours Inc shares had fallen by 11.6% this quarter and lost 13.4% so far this year The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​ five analysts negatively revised earnings estimates The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the electronic equipment & parts peer group is also "buy" Wall Street's median 12-month price target for Dupont De Nemours Inc is $81.00 This summary was machine generated from LSEG data May 2 at 11:00 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) Copyright © 2025 FactSet Research Systems Inc.© 2025 TradingView The investment includes $2.5 million for a real-life pediatric nursing training unit at UCF’s Dr Phillips Nursing Pavilion and $2.5 million for an interdisciplinary research impact fund As UCF’s first pediatric health-focused Pegasus Partner Nemours Children’s Health is helping to address a pediatric workforce shortage and improve the health of children in Central Florida and beyond Nemours Children’s Health, one of the nation’s largest multistate pediatric health systems, will invest $2.5 million in pediatric nursing education, training, innovation and research at UCF’s Dr. Phillips Nursing Pavilion “Strengthening and solidifying the pediatric nursing workforce into the future starts with leading-edge education training and development of emerging clinicians and nurse scientists today,” says Matthew Davis enterprise physician-in-chief and chief scientific officer for Nemours Children’s Health “This Pegasus Partnership emphasizes our institutions’ shared commitment to education and also furthers our ability to provide high-quality pediatric care and ultimately meet the needs of the patients and families we serve.” Building upon UCF’s global expertise in healthcare simulation education and Nemours Children’s clinical excellence the new Nemours Children’s Health Nursery and Pediatric Unit will be a hub of training It will be designed to resemble a real-life pediatric hospital unit Simulation scenarios will give UCF nursing students hands-on clinical experiences to help them provide high-quality compassionate care for pediatric patients and their families Nursing faculty members will collaborate with colleagues across UCF’s healthcare disciplines on research to innovate pediatric education and improve the health of children “We are thankful for Nemours Children’s continued partnership and support of pediatric nursing excellence at UCF.” — Mary Lou Sole “We are thankful for Nemours Children’s continued partnership and support of pediatric nursing excellence at UCF,” says UCF College of Nursing Dean Mary Lou Sole together we will grow a pediatric nursing workforce of Knight nurses to care for children in our community innovate pediatric clinical practices and positively impact children’s health for generations to come.” Phillips Nursing Pavilion is under construction on UCF’s Academic Health Sciences Campus in Lake Nona a hub of healthcare activity and innovation including UCF’s College of Medicine and Nemours Children’s Hospital The nursery and pediatric unit will be located within the Helene Fuld Health Trust STIM Center on the second floor — a high-tech centerpiece in the new building featuring three times the current simulation space Nemours Children’s investment also will support the 2,100-square-foot Nemours Children’s Health Learning Studio one of three high-tech classrooms located off the Collaboration Concourse The studio will feature an innovative active learning design to facilitate collaboration and small-group work This investment expands upon Nemours Children’s partnership with UCF’s College of Nursing Nemours Children’s already participates in UCF’s College of Nursing clinicals program providing clinical rotations for 120 UCF nursing students in 2024 to gain valuable Nemours Children’s Health became UCF’s first pediatric health-focused Pegasus Partner UCF and Nemours Children’s will collaborate on opportunities and initiatives that leverage their collective healthcare and academic excellence to advance children’s health — including the launch of a $2.5M Nemours Impact Fund an interdisciplinary research collaboration agreement to advance pediatric healthcare and improve children’s health outcomes at individual and population levels UCF and Nemours Children’s are creating a talent pipeline of skilled, pediatric healthcare providers to address the pediatric workforce shortage. Nemours Children’s previously established the UCF College of Medicine — Nemours Children’s Health Department of Pediatrics to train the next generation of pediatric physicians With its investment at UCF’s College of Nursing Nemours Children’s is educating and training future pediatric nurses According to the Children’s Hospital Association 35% of children’s hospitals across the U.S are facing a shortage of pediatric registered nurses Around 85% of UCF’s 16,000 Knight nurse alumni remain in Florida to live and work growing the workforce at healthcare facilities including Nemours Children’s Hospital After its anticipated opening in Fall 2025 Phillips Nursing Pavilion will enable UCF to graduate 50% more newly licensed nurses to address the nursing shortage as well as fuel innovation and research Wednesday's ceremony marked the completion of a leading-edge 24-bed inpatient facility at Nemours Children's Hospital the first phase of the Moseley Foundation Institute features a family-centered state-of-the-art design that overlooks the beautiful gardens of the Nemours Estate to promote healing and recovery The second phase of the Moseley Foundation Institute will feature a 19,000-square-foot outpatient Day Hospital and Infusion Center expected to open in October 2025— more than quadrupling its current size "Today marks a monumental milestone as we open our doors to this extraordinary facility which will allow us to bring the very best research and clinical care to more children with cancer and blood disorders," said Mark R Delaware Valley. "The opening of this facility and the continued growth as we anticipate the second phase of the project will allow Nemours Children's to provide world-class services right here in the Delaware Valley to children with these illnesses We are deeply grateful to the Moseley Foundation for this transformative gift." The vision for the Moseley Foundation Institute began in March 2023 with the gift from the Moseley Foundation As one of the most significant donations ever made to a U.S the donation amplifies Nemours Children's ongoing efforts to improve both the outcome and the experience of care for children with cancer sickle cell disease and other blood disorders Nemours leaders anticipate both immediate and long-term benefits for patients "This beautiful facility bears testament to Mrs Moseley's desire to improve children's health and specifically to advance health outcomes related to cancer and blood disorders I believe that she would be particularly proud of the work Nemours Children's is doing to address health disparities in the community where she was raised We are honored that her legacy will fuel research and scholarship that will have an impact not just in Delaware but across the country and around the world," said William J President of the Lisa Dean Moseley Foundation In addition to the new inpatient facility and Day Hospital and Infusion Center the Moseley Foundation Institute encompasses several initiatives aimed at improving clinical care and research "The extraordinary gift from the Moseley Foundation further empowers Nemours Children's to catapult development of new treatment options for the benefit of pediatric patients with cancer sickle cell disease and other blood disorders," said David C Chair of Pediatrics at Nemours Children's Health "We are delighted to open our doors to our first patients We look forward to providing these patients and their families with the finest Nemours Children's has achieved many accolades in hematology and oncology research and care including: To learn more about how this gift will impact the future of care for kids with cancer and blood disorders, please visit: nemours.org/moseleyinstitute The Nemours Foundation, established through the legacy and philanthropy of Alfred I. duPont, provides pediatric clinical care, research, education, advocacy, and prevention programs to the children, families and communities it serves. For more information, visit Nemours.org the Lisa Dean Moseley Foundation is a non-profit organization that supports basic medical and scientific research The Foundation generally accomplishes these goals by collaborating with and funding research and clinical programs undertaken by highly qualified organizations such as Nemours Children's Health and the Cleveland Clinic (among many other research institutions supported by previous grants made by the Foundation) The Lisa Dean Moseley Foundation strives to support groundbreaking research and clinical programs with the goal of improving outcomes and saving patient lives.  Nemours Children's Health and the State of Delaware today announced an agreement to create a transformational new effort aimed at making Delaware's.. Nemours Children's Health announced several significant investments today including plans for a groundbreaking Maternal and Fetal Health Program,.. Health Care & Hospitals Medical Pharmaceuticals Not For Profit Children Do not sell or share my personal information: DuPont de Nemours (NYSE:DD - Get Free Report) updated its second quarter 2025 earnings guidance on Friday The company provided earnings per share (EPS) guidance of 1.050-1.050 for the period The company issued revenue guidance of $3.2 billion-$3.2 billion compared to the consensus revenue estimate of $3.3 billion DuPont de Nemours also updated its FY 2025 guidance to 4.300-4.400 EPS DD has been the topic of a number of recent research reports KeyCorp upped their price objective on DuPont de Nemours from $81.00 to $85.00 and gave the company an "overweight" rating in a research report on Monday Mizuho lowered their price target on DuPont de Nemours from $100.00 to $80.00 and set an "outperform" rating for the company in a research report on Tuesday Morgan Stanley reduced their target price on shares of DuPont de Nemours from $94.00 to $80.00 and set an "equal weight" rating on the stock in a research note on Monday BMO Capital Markets lifted their price target on shares of DuPont de Nemours from $105.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday Wells Fargo & Company reduced their price objective on shares of DuPont de Nemours from $105.00 to $81.00 and set an "overweight" rating on the stock in a research report on Wednesday Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.07 Check Out Our Latest Research Report on DD Shares of DD traded down $1.83 during midday trading on Monday 3,161,242 shares of the stock were exchanged compared to its average volume of 2,417,503 a quick ratio of 0.88 and a debt-to-equity ratio of 0.22 DuPont de Nemours has a 52 week low of $53.77 and a 52 week high of $90.06 The company's 50 day moving average is $69.81 and its two-hundred day moving average is $76.59 The company has a market capitalization of $27.38 billion DuPont de Nemours (NYSE:DD - Get Free Report) last announced its quarterly earnings results on Friday The basic materials company reported $1.03 earnings per share for the quarter topping the consensus estimate of $0.95 by $0.08 The firm had revenue of $3.07 billion during the quarter compared to analysts' expectations of $3.05 billion DuPont de Nemours had a net margin of 5.47% and a return on equity of 7.12% The company's revenue was up 4.6% compared to the same quarter last year sell-side analysts anticipate that DuPont de Nemours will post 4.38 earnings per share for the current year The business also recently disclosed a quarterly dividend May 30th will be paid a dividend of $0.41 per share This represents a $1.64 dividend on an annualized basis and a dividend yield of 2.51% DuPont de Nemours's dividend payout ratio (DPR) is currently -863.16% An institutional investor recently raised its position in DuPont de Nemours stock. Brighton Jones LLC increased its position in DuPont de Nemours, Inc. (NYSE:DD - Free Report) by 19.6% in the fourth quarter according to its most recent 13F filing with the Securities and Exchange Commission (SEC) The fund owned 5,012 shares of the basic materials company's stock after acquiring an additional 822 shares during the period Brighton Jones LLC's holdings in DuPont de Nemours were worth $382,000 as of its most recent filing with the Securities and Exchange Commission (SEC) Institutional investors own 73.96% of the company's stock Market downturns give many investors pause Enter your email address to learn more about using beta to protect your portfolio Our #1 AI Stock Pick is on a steep discount - 29.99$ instead of 99.99$! Click here to access exclusive research DuPont de Nemours, Inc. (NYSE:DD) Q1 2025 Earnings Call Transcript May 2 and welcome to the DuPont First Quarter 2025 Earnings Call All lines have been placed on mute to prevent any background noise there will be a question-and-answer session [Operator Instructions] I would now like to turn the call over to Ed Barna and thank you for joining us for DuPont’s first quarter 2025 financial results conference call current Electronics Business President and CEO – elect of the future Independent Electronics company; and Antonella Franzen We have prepared slides to supplement our remarks which are posted on DuPont’s website under the Investor Relations tab and through the webcast link Please read the forward-looking statement disclaimer contained in the slide we will make forward-looking statements regarding our expectations or predictions about the future Because these statements are based on current assumptions and factors that involve risks and uncertainties our actual performance and results may differ materially from our forward-looking statements as updated by our current and periodic reports includes a detailed discussion of principal risks and uncertainties all historical financial measures presented today are on a continuing operations basis and exclude significant items We will also refer to other non-GAAP measures A reconciliation to the most directly comparable GAAP financial measure is included in our press release and presentation materials and have been posted to DuPont’s Investor Relations website I’ll now turn the call over to Lori we reported solid first quarter results ahead of our previously communicated guidance First quarter sales grew 6% on an organic basis on strong volume growth Operating EBITDA of $788 million increased 16% year-over-year demonstrating strong leverage in the quarter Operating EBITDA margin of 25.7% increased 240 basis points from prior year we saw continued broad-based demand in electronics driven by strength in semi-advanced nodes and AI applications and strong volume growth in our healthcare and water businesses We continue to see strong order patterns through April I am pleased with the continued progress that our teams are making on the intended spin-off of our electronics business we recently achieved several key milestones which enables us to remain on track for our November 1st separation date we completed key executive leadership appointments current DuPont Electronics Business President Jon is well-positioned to lead the future independent company given his proven leadership and extensive experience in the semi space and broader electronics industry We are pleased to have Jon on the call with us this morning Matt has an impressive track record as a public company CFO along with deep experience in spin-off transactions and will serve as a valuable business partner to Jon we’ve made significant progress on the composition of the Qnity Board This is a group of highly accomplished leaders with a global business experience we submitted the initial filing of the Form 10 registration statement with the SEC This document contains detailed business and financial information related to the future standalone company as well as information related to the separation which details how we are addressing tariff uncertainty We are a global organization with presence in all key regions including a significant manufacturing footprint in the U.S Our scale provides ample flexibility to adjust production and product flow the vast majority of our raw material buy is purchased in the region it is consumed and is not subject to the new tariffs Our teams have been carefully analyzing ongoing global supply-chain dynamics engaging with our customer and supplier base and actively working on a number of tariff mitigation actions our estimated cost exposure in 2025 before mitigation action is about $500 million on an annualized basis We have identified actions to substantially offset this potential headwind with the net cost impact in 2025 currently estimated at about $60 million which primarily would impact the second half We continue to evaluate additional measures in order to further minimize the potential impact we have a solid game plan to continue to consistently deliver results and we are executing well and advancing our strategic priorities I am honored to be here today as CEO of Elect of the Future Independent Electronics Company reflecting the collaborative way we work with our customers Qnity will be one of the largest pure-play electronics materials and solutions providers in the industry with $4.3 billion in net sales in 2024 We have a broad portfolio and customer relationships founded on a heritage that spans more than 50 years As the partner of choice for our customers we have a seat at the design table working to advance their technology roadmaps enabling the next generation of advanced computing and connectivity applications we offer a diverse portfolio serving the entire electronics value chain from chip fabrication and advanced packaging to advanced interconnects We bring material science expertise and end-to-end engineering solutions across the full breadth of our portfolio to deliver world-class innovation to our customers Qnity is well-positioned to benefit from robust growth in semiconductor markets while leveraging a strong financial profile with about 60% of net sales in semiconductors the company will compete with a set of recognized global semi participants and we expect to attract an investor base commensurate with this profile We have long-term relationships with all key semiconductor and other electronics OEMs in the industry and a strong history of co-development and application engineering to ensure customer success the business is well-equipped to continue to participate in the AI-driven growth acceleration via our advanced node semi-products and advanced packaging applications for use in data centers and personal devices We further enable key AI applications with high-density interconnect products and layered thermal management solutions We believe these leading positions will continue to drive industry outperformance for the future electronics company we continue to make very good progress on the separation and I look forward to working more closely with our future Board I will now turn the call over to Antonella to cover the financials and outlook I am pleased with the solid start to the year as increased volumes across many key end-markets and continued operational focus by our teams drove strong financial performance in the first quarter I would also like to remind you that we realigned our segment reporting structure during the quarter The segment results now reported as ElectronicsCo and IndustrialsCo Beginning with first quarter financial highlights on Slide 6 net sales of $3.1 billion increased 5% versus the year-ago period as 6% organic sales growth was slightly offset by a currency headwind of 1% Organic sales growth consisted of an 8% increase in volume partially offset by a 2% decrease in price both segments saw organic sales growth with ElectronicsCo and IndustrialsCo up 14% and 2% Volume gains during the quarter were led by double-digit growth in our businesses serving electronics Asia Pacific delivered 13% organic sales growth year-over-year including another strong quarter of growth in China Organic sales were up 4% in Europe and flat in North America given the soft construction and auto markets First quarter operating EBITDA of $788 million increased 16% versus the year-ago period as volume gains and savings from prior year restructuring actions were partially offset by growth investments Operating EBITDA margin during the quarter of 25.7% increased 240 basis points year-over-year operating cash flow for the quarter of $382 million and $79 million of separation-related transaction cost payments resulted in transaction-adjusted free cash flow of $212 million and related conversion of 49% first quarter cash flow is inclusive of our annual variable compensation payout We expect cash flow conversion to accelerate as we move through the year with full-year conversion of greater than 90% Adjusted EPS for the quarter of $1.03 per share increased 30% from $0.79 in the year-ago period as well as below-the-line benefits totaling $0.05 ElectronicsCo’s first quarter net sales of $1.1 billion increased 14% versus the year-ago period on both a reported and organic basis due to a 16% increase in volume organic sales for Semiconductor Technologies were up low-double-digits on strong end-market demand driven by advanced nodes and AI technology applications Semi demand in China continued to be strong with better-than-expected growth driven by timing shifts from second quarter into first quarter Interconnect Solutions also posted another strong quarter with organic sales up high teens volume gains from AI-driven technology ramps and continued benefits from content and share gains Operating EBITDA for ElectronicsCo of $373 million was up 26% versus the year-ago period as volume benefits were partially offset by continued growth investments to support advanced node transitions and AI technology ramps Operating EBITDA margin during the quarter was 33.4% up 340 basis points versus the year-ago period IndustrialsCo’s first quarter net sales of $1.95 billion were flat versus the year-ago period as a 2% organic sales growth was offset by a 1% currency headwind and a 1% unfavorable portfolio impact Organic sales growth of 2% reflects a 3% increase in volume partially offset by a 1% decrease in price In connection with the first quarter Segment Realignment we have organized IndustrialsCo into two lines of business Healthcare & Water Technologies consists of our high-growth businesses of healthcare and water Our healthcare portfolio includes Tyvek medical packaging and garment offerings Spectrum and Donatelle advanced medical device applications and Liveo Biopharma processing and solutions Our water business is a leading technology provider with a comprehensive portfolio of filtration technologies Water also has strong exposure to secular growth drivers and serves key end-markets such as industrial water and energy Diversified Industrials is a leading provider of innovative products and solutions supported by well-known brand names serving industrial-based end markets Healthcare and Water Technology sales were up low-teens on an organic basis versus the year-ago period reflecting volume gains in all business lines within Healthcare and strength in Water led by reverse osmosis Diversified Industrials sales were down mid-single-digits on an organic basis due primarily to softness in construction and auto end-markets Operating EBITDA for IndustrialsCo during the quarter of $464 million was up 6% versus the year-ago period due to volume gains and savings from prior year restructuring actions Operating EBITDA margin during the quarter was 23.8% up 130 basis points from the year-ago period which outlines our latest view on 2025 financial guidance we estimate net sales of about $3.2 billion These estimates include a seasonal sequential sales lift although muted from prior expectations given timing shifts from the second quarter into the first quarter in semi we are maintaining our guidance at our prior outlook with estimates for net sales of $12.8 billion to $12.9 billion operating EBITDA of $3.325 billion to $3.375 billion and adjusted EPS of $4.30 to $4.40 per share we currently estimate a net cost impact of tariffs of about $60 million or about $0.10 per share mainly related to the second half of the year Our financial guidance does not include this estimated net cost impact as we continue to identify further mitigation actions as well as tariff implementation uncertainty I am pleased with a solid start to the year and want to thank our employees for delivering these results and for their ongoing support to the separation process and let me turn it back to the operator to open the Q&A Your first question comes from the line of Jeffrey Sprague with Vertical Research I was just wondering if you could just walk us through sort of the exemption process how many kind of different exemptions do you need or do you have And most of what you need relative to this guide is that in-hand at this point when we think about all of the tariff actions that we’re pursuing in terms of supply-chain adjustments is probably the smallest of those four categories the bulk of the tariff savings and mitigation actions that we’ve done have really been on the procurement and supply-chain optimization side of the house We continue to have very constructive dialogue particularly in the semiconductor industry It’s a relatively small percentage of our total mitigation strategy and we continue to have those dialogs with the teams on the ground And then so on the supply-chain optimization side then does that imply that you’re sourcing from Europe now or somewhere else into China to get around the need for exemptions what you’re actually doing on the supply-chain side and sourcing So when we think about our supply routes into China very little of what we produce in China actually comes from the U.S It’s a very small percentage of the total Most of what we buy for our products in China we’re all sort of – we’re sort of positioned well already given the extensive footprint across the industry And in the handful of places where we do have U.S.-sourced materials we have alternatives of suppliers that we’ve been working with our customers to shift to those alternative suppliers that wouldn’t have any difficulty with the tariffs that’s – those are materials are already qualified there’s a little bit of a timing lag to make sure that we can qualify those new materials we’re really well-positioned within the electronics space where we’re already buying our materials the total company number for sales that we export from the U.S So the bulk of the gross impact that we sized at $500 million on an annual basis is us moving intermediate product into China toward final completion and then shipping to the customer And so that’s why we’re able to flex our own supply chain internally to be able to mitigate a lot of that impact it’s not actually shipping finished product into China that – those intermediates can come from other places as part of the sourcing changes and optimization then Operator: Your next question comes from the line of Scott Davis at Melius Research Scott Davis: And congrats on all this stuff I wanted just to see if you could give us the tariff numbers broken down into the two businesses just starting to think about DuPont as completely separate You have that data available between Qnity and for DuPont So just a couple of comments related to that So when you look at our net exposure for 2025 it’s actually split pretty evenly between ElectronicsCo and IndustrialsCo So about $30 million in each is kind of the way to think about it When you think about our exposure relative to a percent of our COGS it’s actually around 6% for both ElectronicsCo and IndustrialsCo The one other thing that I would just mention and bring up related to the impact the in-year impact being about $60 million that’s predominantly in the second half of the year and assume nothing changes from where we are today you don’t walk away thinking the $60 million becomes $120 million next year and that we have an incremental $60 million headwind we do have additional incremental mitigating actions that Some of it relates to qualifying certain products in different areas So we have incremental mitigating actions that will come into play towards the end of the year that will help mitigate any further impact that we would have in 2026 assuming there is no changes from where we are right now And just to follow-up on Jeff’s question that $200 million of intermediate product that’s being shipped to China how – would there be a long-term plan to try to locate that That’s one of the reasons why you’re shipping it from here to there Just trying to get a sense of just – the challenge of moving that asset base or whether this is a bit of a – kind of permanent structural issue So the $200 million was the finished product export sales from the U.S that’s the bulk of the gross exposure of the $500 million that we size That we’ve got continuing actions that we can take either on our own supply chain or favorable outcomes on the exemptions or ultimately pricing actions in excess of the surcharges that we’re putting in place we get to the place where it’s really not a net impact for us but it’s not moving your own fixed assets Operator: Your next question comes from the line of Steve Tusa with JPMorgan how much of these sales in China do you think – are you like stepped in on with like long-term contracts with your – with the OEMs there or whoever is buying and integrating your products and the finished product what percentage of those sales can they kind of substitute So when you think about from an electronics point of view we had about $1.4 billion of sales into China I would say almost half of that went to multinational company sales and almost 100% of those multinational company sales There is an additional probably 25% to 30% that go to the semi-customers Where we have what we would call a process of record identified which means that we’re specked into their particular technologies So switching us out immediately for a competitor and there’s a lot of cost involved in making that switch and we get to a point where north of 70% of our sales into China And then you don’t really have anything that’s like That’s not really the issue here when you’re shipping to China Operator: Your next question comes from the line of John McNulty with BMO Capital Markets Maybe a little bit of a shift away from the tariff question We’ve been seeing some of the water markets starting to accelerate a bit but you guys seem like you’re definitely at the high end of some of the results that we’re seeing as to what that demand is really stemming from if there’s any specific end markets or industries that are maybe driving that that would be helpful So we’ve – we did have really nice results in water in the quarter and we expect water to be up kind of high single – mid to high single-digits for the year So a piece of it is the favorable comp from last year was our low point for the Water business as we saw the tail-end of the destocking the demand is very strong across the main technologies whether it’s RO with all of the desalination requirements Ion exchange is where we get more diversification from an end-market and application perspective whether it’s in microelectronics for purification of water or within food and beverage for purification of water there is some key nascent technologies that we’re following that but present nice upside for us as we go forward especially around PFAS cleanup and the DLE so the direct lithium extraction opportunity for us to have the water opportunity in the portfolio And then just another question on the ElectronicsCo side you’ve spoken to some of your AI exposure You specifically called out the Interconnect Solutions side and some of the AI-driven technology ramps can you help us to understand the size of that business in Interconnect Solutions and some of the applications that you’re helping to address there we sort of talked about sort of AI and particularly kind of the data center and high-performance computing exposure And part of that is comprised of the advanced chips that And then the rest of it is sort of in advanced packaging So data center for us is about 15% of our portfolio It was actually up mid-teens in the quarter really with the growth across all of those categories of the advanced chip Operator: Your next question comes from the line of Christopher Parkinson with Wolfe Research what you’re seeing across both semi-tech and ICS And how you’re thinking about the China market versus just the non-China market in terms of how things are evolving thus far in 2Q and how that could potentially lead to second half trends China is the – China growth has really been driven by fairly strong domestic demand in China as well as a bunch of new fab start-ups that are taking place typically you’re running a lot of material because you’re starting out with a fairly low yield the material consumption is a little bit higher And then this – the underlying demand in China As we think about the China demand in semi going forward we think that normalizes to – so it doesn’t have kind of the elevated it normalizes to a more normal demand level and we are expecting about flat for the full year those customers are operating kind of most So there’s not really pull-forward dynamics that are happening in the ICS markets it’s more real-time production and that demand continues to be strong both in China and really in the rest of the world we’re expecting high single-digit growth from both semi and ICS for the rest of the year we see demand really being driven by the AI and advanced packaging applications continuing through the year And that’s really what’s fueling most of the growth Advanced logic and DRAM continue to have high utilization rates And then it’s the – as we’ve talked about before if we see any uptick in mature logic and NAND that would probably give us some nice upside And those – that commentary is pretty consistent with what I think what you’ve heard from our customer base in the broader market you’re kind of leading into my follow-up When we think about your exposure in packaging and circuit materials we think about kind of the intermediate to long-term trends in HPC can you just talk about your competitive positioning what are we going to be talking about as we approach November 1 ’27 earnings in terms of that specific business So we’re excited about our position We got a terrific position in both the advanced nodes and the advanced packaging and cleans continues to be a very strong business for us And as we go forward into ’26 and ’27 one of the exciting opportunities is just starting to see some of those CMP processes that are used today on the front-end of the line in the semi-world Moving into the back-end of line into some of the packaging That will help contribute to kind of what I would call content growth in the semi-process because today you’re only using those steps mostly on the front-end And as you start to see those processing steps needed on the back-end that will be some nice upside opportunity for us you know where we have a broad set of materials going into that market We’re well-positioned on both metalization materials and thermal materials in particular some of the foundry customers to be able to scale-up their 2.5D and 3D packaging technologies including some of the vertical scaling that may happen in some of the outer parts of the time horizon that you mentioned that also represents additional upside for us we are seeing some nice share gains in the advanced packaging space in particular And in our Interconnect Solutions business where we’ve seen some nice share gains over the last few quarters Operator: Your next question comes from the line of Josh Spector with UBS and just kind of the logic of not changing the guidance are you messaging that there is potentially more offsets that could then get you into your original guidance range or is it just uncertainty and you didn’t want to adjust yet it’s kind of been a moving target day-by-day So we wanted to keep our underlying guidance clean so you can see our operational performance really hard to offset the impact of the tariffs We started with a $500 million annualized number Our impact for the year currently is around $60 million There clearly could be some incremental mitigation actions that we have in-place We’ll see what position we’re in And then we’ll – depending on where things kind of land the China anti-competitive review that’s going on Tyvek can you comment on that beyond what you guys had in the press release a month or so ago if you can say anything about the potential or lack of potential for further China reviews to spread to other parts of the business Is that a risk that you’re worried about or is it something that you’re not worried about So on the second part of your question first we don’t see a risk of it going beyond the initial Tyvek investigation So the investigation is kind of at a steady point So we comply very quickly with all of their requests So it’s not a huge number for the total company we don’t see it creeping into other areas of the business Edward Breen: And the documents that we turned over to them were all related to just the Tyvek business And the only thing I would add is while this is ongoing we are able to continue to sell to customers within the area Operator: Your next question comes from the line of David Begleiter with Deutsche Bank our Kevlar and Nomex core to the new DuPont So we – we’ve been talking when we made the decision to keep the water business that we would build around the high-growth components of the portfolio and we would look to take complexity out over time start to reduce the end-markets in which we play So I don’t want to comment any further on the speculation around the news from the Aramids business beyond saying that we’ve been pretty vocal about differentially investing and driving growth around the healthcare and water can you quantify the impact of the pull-forward of semiconductor technology earnings into Q1 versus Q2 that was – we sized that around $30 million of sales that went into the first quarter from the second quarter That’s at a pretty high-margin rate Operator: Your next question comes from the line of John Roberts with Mizuho Could you give us a little more granularity for the Diversified Industrials segment and will the 10-Q have any more additional reporting within that kind of sub-segment So the Diversified is primarily comprised of the Shelter business which is our auto and aerospace exposed businesses And the remainder is printing and publishing that came over which was reported within the Industrial Solutions space You’ll see that we’re disaggregating revenue for the new DuPont company at two levels So you’ll see today the Healthcare and Water under one segment and then Diversified Industrials underneath another segment we’ll have to disaggregate that even farther So you would see most likely the areas that and then you would see that Healthcare and Water separately for Healthcare and Water Operator: Your next question comes from the line of Patrick Cunningham with Citi You noted share gains pretty consistently for electronics I’m just wondering in the current sort of environment where we’re seeing normalization and tariff uncertainty do you see any pressure on that outperformance whether it’s additional competitive dynamics Our teams have been – we’re fighting the battles kind of on the street Our teams are in constant contact with our customers and we’re watching that really closely We feel good about our competitive position The dialogue that we have with our customers is strong which our customers continue to work towards more advanced technologies with increasing process complexity and increasing quality requirements there is not as many participants who can help them to maintain the quality and the yields that they need in their facilities whether you’re talking a semiconductor chip And we supplement that with large groups of application engineers in the local geographies where our customers are at to help them optimize their production really Our engineers are working side-by-side with them in the factory to help them optimize how our products are used to maximize their performance And that’s part of the value proposition that we bring and part of why we have kind of a seat at the design table with them Like could fresh restrictions be a potential retaliatory measure in this trade environment Jon Kemp: I think it’s – we watch that closely It’s certainly a dynamic environment We don’t have anything kind of scoped out that we’re anticipating at the moment as we’ve seen since going all the way back to 2019 that it continues to be a dynamic environment and we’ll continue to watch it closely I think things have demonstrated an ability to navigate those changes pretty well Operator: Your next question comes from the line of Aleksey Yefremov with KeyBanc Capital Markets your full year sales guide is for 3% to 4% growth that’s acceleration from flat in 1Q So what would get better here and year-on-year I think you’re mixing as reported in organic our organic sales for Industrials were 2% up we’re kind of forecasting low-single-digits and we had mentioned that we were trending towards the lower end versus the total company reported basis – total sales So not much of a change in trends sounds like Aleksey Yefremov: And just going back to – okay so you mentioned the pull-in from Q1 – from Q2 into Q1 you’ve been talking about also potential some of the give-backs from strong sales in China that you could see in ’25 Is that still on the table sometime later in ’25 I think our guide – has it normalizing kind of through the rest of the year As we continue to see kind of the customers and part of that is whatever materials they have we expect will be consumed based on demand they continue to see fairly strong local demand and that they’re not talking about hugely elevated inventories We do expect that there will be some normalization we’ll have to monitor how that goes we still expect the markets to be fairly strong especially in some of the advanced technologies that I’ve talked about a lot of – China has got data center activity going on and automotive business that they’re supporting Their consumer electronics businesses have been fairly strong And as we see that kind of pan-out globally we think that demand conditions – what we’re hearing from our customers is those demand conditions should continue Operator: Your next question comes from the line of Mike Leithead with Barclays my understanding is Water and some of the Industrials businesses are often sold through distributors do you have any sense of channel inventories and any impact to potential pre-buying in that segment So that’s what’s kind of driving up the average But we – in Water to your specific question we saw all of the destock activity kind of as we headed into the tail-end of ’23 and we don’t see anything building there again I wanted to follow-up on the Aramids business I appreciate the disclosure around what drove the timing But can you just talk a bit more about what drove the write-down or was it long ago closer to when the merger occurred Just some sort of context on that would be helpful there was actually no significant changes to the future cash flows of the business at all What happened was really more accounting-related is how I would characterize it So you got to keep in mind that we – as we redid our segments we had to re-identify what our reporting units were So Aramids is now a standalone reporting unit You heard us talk about that kind of in the 10-Q when we would do our annual impairment test So there was other businesses within there as well When you pull Aramids out on a standalone basis no changes to what was expected in terms of performance But when you look at the carrying value versus the fair-value the carrying value – the fair-value was lower so we had to take the impairment charge during the quarter So it all stemmed from the realignment of the businesses during Q1 Operator: Your next question comes from the line of Mike Sison with Wells Fargo how should investors think about sort of the right companies to compare you with And the thought was semiconductor materials and equipment folks but you’ve seen pretty significant multiple compression at Entegris and others a lot of the higher-quality materials companies like the Linde So how do you think about the right comps for your business and how we look to value the company post-spin I still think that the industry – the semi-industry pure-plays are still probably the best peer set for us I recognize there’s been a little – there’s been some compression in the short-term the industry dynamics are still very favorable with long-term growth and where we’re going broadly across the electronics space And I think that will support kind of over-time that will support a long-term very nice valuation for us and for others in the electronics industry I’m curious if you’d like to opine on AI There’s a lot of cost – a lot of questions on whether we peak that’s probably a good driver for this business longer-term I think we’re – we continue to believe that we’re still in the very early days of the AI — the adoption of AI use cases and that there’s still a lot of opportunities for further adoption and further growth I think that’s been reaffirmed a lot by the hyperscalers that have come out they’re not pulling back their investment They’re increasing the size of their investment in this space I kind of sized it with kind of the data center number that It’s about 15% of the portfolio and it was up mid-teens It’s a big part of our Advanced Packaging business as well which is about 10% of the portfolio and it was up in the low-20s in the first-quarter And we continue to see opportunities for market expansion as well as for share expansion And we see more-and-more adoption of use cases become more broadly affordable for more people it comes back-down to needing more compute and more connectivity and both of those trends support growth for our business Operator: Your next question comes from the line of Frank Mitsch with Fermium Research I wanted to drill into the IndustrialsCo side of the house Obviously very strong in the Healthcare and Water did low-teens I believe that initially there was a thought that the Healthcare and Water side would grow mid to-high single-digits and having done low-teens in the first-quarter what your thoughts are for the balance of the year what your thoughts are in terms of growth rates on that side of the business we’re still in the same zone for the full year growth for Water and Healthcare as you had mentioned so Healthcare being up more in the high-single-digits in Water mid to-high single-digits And we actually see them lifting as we go through the year from new system implementations being put in-place in the second half pickup on the med device side that’s driving the growth there On – with the first quarter being up 14% and 11% organically for those businesses was a function of strong markets which as you – we had mentioned earlier in the call the water was low from the completion of the destock and we were still seeing the destock on the Tyvek medical packaging side in the first quarter of last year So we do see those growth rates moderating the 4% organic decline was really driven by Shelter and Automotive So those businesses are well-telegraphed to be softening Shelter kind of across mainly the largest soft is filling on the residential side and the do-it-yourself side And the revisions that came out from IHS in this last cycle so the full year goes down about 120 basis points We do see a little bit of a pickup in the second half really around the personal protection space and the aero piece of industrial remaining strong as I had mentioned in Healthcare and Water And just a follow-up on the billing and construction May for 2Q relative to how they are historically What – how could you characterize your – the order books there We had mentioned April turned out strong for us we typically start with about 75% of the orders on the books for the month We haven’t seen any slowdown in orders We actually and usually see orders tick up as you start the year no change in momentum from that perspective Operator: Your next question comes from the line of Vincent Andrews with Morgan Stanley And wondering if you can give us an update on PFAS and whether you think there’ll be any material developments between now and November spin either in the state attorney generals it doesn’t seem like anything big will happen until at the early kind of going towards the tail-end of this calendar year but that will – it’s in phases so that will probably most likely go through the whole summer And then the – I’d say the bigger issue is the personal injury ones and the first bellwether cases for that are in October of this year So really nothing imminent in the kind of the next six months Operator: Your next question comes from the line of Arun Viswanathan with RBC Capital Markets Maybe I could just ask a question about the logistics of the spin is there – is it possible that you could pursue any M&A ahead of the spin You talked about growth in Healthcare and Water possibly monetize some – and could you potentially monetize any other assets ahead of the spins or is that something that we should expect after November 1 I would say probably nothing material before the November 1 all hands on deck to get the November 1 separation complete but we are actively looking at areas where we can either add to the portfolio And I’ll speak to Remainco and maybe Jon can talk a little bit too in Qnity But we’re always looking and have a robust pipeline But there’s nothing that I would say is imminent but it would happen before the November 1 separation Jon Kemp: And I would be – for Qnity it would be very similar to how Lori characterized it have you seen any change in your order patterns amongst some of the industrial customers maybe in different countries on the water side Do you see any change in behavior as far as pulling back or maybe extending out orders as it relates to tariffs or have – that momentum kind of continued We haven’t seen any oddities in the order patterns for New DuPont The order book is consistent with our expectations as we see it through the second quarter Operator: Our next question will be Steve Byrne the EPA put out their PFAS – PFAS action item list and I’m really anxious to hear your view of it It is quite detailed and quite a few action items It seems to be a little bit of a different approach than the way they’ve taken on to cut lots of other environmental regs But a couple of items in there that I wonder what your view is like they’re proposing to develop some affluent guidelines you had mentioned the potential benefit in your water business from treatment for PFAS maybe affluent guidelines could assist in that although they might cut or change drinking water standards And the other one they’ve highlighted whether or not you think that could have an effect on some of the future litigation there’s no change right now on the opportunity side within the water business to address the PFAS cleanup and remediation work we continue to make progress within the South Carolina MDL our exposure is most like most concentrated So we got large one out-of-the way like a year and a half ago with the water districts as Ed had mentioned on the Bellwether cases on the personal injury front start in October and then we continue to manage our own kind of state-by-state exposure But we’ll read-through the document and see if there’s any changes to our current views Edward Breen: And remember the personal injury case is coming up So I think the parameters we had in the last big settlement would clearly apply here also This $200 million of finished goods shipments from the U.S And so the tariff would be on them with respect to payment we’re working to make sure that maybe all the exemptions that could mitigate that piece for them would be in-place evenly that split kind of evenly between Electronics and IndustrialsCo that $200 million Operator: Question-and-answer session for today I will now turn the call over back to Ed Barna Ed Barna: Thank you everyone for joining today a copy of our transcript will be posted on DuPont’s website Artificial intelligence is the greatest investment opportunity of our lifetime The time to invest in groundbreaking AI is now My #1 AI stock pick delivered solid gains since the beginning of 2025 while popular AI stocks like NVDA and AVGO lost around 25% The numbers speak for themselves: while giants of the AI world bleed showcasing the power of our research and the immense opportunity waiting to be seized Artificial intelligence isn’t science fiction anymore It’s the revolution reshaping every industry on the planet From driverless cars to medical breakthroughs and savvy investors stand to reap the rewards Here’s why this is the prime moment to jump on the AI bandwagon: Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory and automated logistics that streamline everything This isn’t a maybe – it’s an inevitability Early investors will be the ones positioned to ride the wave of this technological tsunami Ground Floor Opportunity: Remember the early days of the internet Those who saw the potential of tech giants back then are sitting pretty today We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon This is your chance to get in before the rockets take off Disruption is the New Name of the Game: Let’s face it and it’s shaking the foundations of traditional industries while the dinosaurs clinging to outdated methods will be left in the dust The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI From computer scientists to mathematicians the next generation of innovators is pouring its energy into this field This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements you’re essentially backing the future The future is powered by artificial intelligence Don’t be a spectator in this technological revolution Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation This isn’t just about making money – it’s about being part of the future buckle up and get ready for the ride of your investment life Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!) and savvy investors stand to make a fortune how do you find the hidden gem – the company poised for explosive growth that even if its stock price quadrupled today it would still be considered ridiculously cheap That’s the potential you’re looking at This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade Our research team has identified a hidden gem – an AI company with cutting-edge technology and a current stock price that screams opportunity This company boasts the most advanced technology in the AI sector It’s like having a race car on a go-kart track They have a strong possibility of cornering entire markets becoming the undisputed leader in their field Here’s the catch (it’s a good one): To uncover this sleeping giant We want to make sure none of our valued readers miss out on this groundbreaking opportunity That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70% For a ridiculously low price of just $29.99 you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal Here’s why this is a deal you can’t afford to pass up: • Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential • 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months These stocks are handpicked by our research director • One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149 • Bonus Reports: Premium access to members-only fund manager video interviews • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads allowing you to focus on uncovering the next big opportunity • 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service we’ll provide a full refund within 30 days Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment 1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.99 exclusive access to our in-depth report on the revolutionary AI company and the upcoming issues of our Premium Readership Newsletter over the next 12 months and know that you’re backed by our ironclad 30-day money-back guarantee Don’t miss out on this incredible opportunity Subscribe now and take control of your AI investment future I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries We’re independently funding today’s broadcast to address something on the mind of every investor in America right now… Should I put my money in Artificial Intelligence Here to answer that for us… and give away his No 1 free AI recommendation… is 50-year Wall Street titan He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC But what Marc’s most known for is his award-winning stock-rating system Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet… and brokerages to track the billions of dollars flowing in and out of stocks each day He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022 Click to continue reading… Get our editor’s daily picks straight in your inbox DuPont de Nemours (NYSE:DD - Get Free Report) updated its FY 2025 earnings guidance on Friday The company provided earnings per share guidance of 4.300-4.400 for the period The company issued revenue guidance of $12.8 billion-$12.9 billion compared to the consensus revenue estimate of $12.7 billion DuPont de Nemours also updated its Q2 2025 guidance to 1.050-1.050 EPS Four investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company DuPont de Nemours presently has an average rating of "Moderate Buy" and a consensus price target of $85.07 Check Out Our Latest Stock Analysis on DD Shares of DD traded down $1.83 during mid-day trading on Monday The stock had a trading volume of 3,161,242 shares The business has a fifty day moving average of $69.81 and a 200 day moving average of $76.59 a quick ratio of 0.88 and a current ratio of 1.33 DuPont de Nemours has a 12 month low of $53.77 and a 12 month high of $90.06 DuPont de Nemours (NYSE:DD - Get Free Report) last issued its quarterly earnings results on Friday The basic materials company reported $1.03 earnings per share (EPS) for the quarter topping analysts' consensus estimates of $0.95 by $0.08 The business had revenue of $3.07 billion during the quarter compared to analyst estimates of $3.05 billion DuPont de Nemours's revenue for the quarter was up 4.6% compared to the same quarter last year Equities analysts predict that DuPont de Nemours will post 4.38 EPS for the current year May 30th will be issued a dividend of $0.41 per share A hedge fund recently raised its stake in DuPont de Nemours stock. Brighton Jones LLC raised its stake in shares of DuPont de Nemours, Inc. (NYSE:DD - Free Report) by 19.6% in the 4th quarter according to its most recent 13F filing with the Securities & Exchange Commission The fund owned 5,012 shares of the basic materials company's stock after purchasing an additional 822 shares during the period 73.96% of the stock is currently owned by hedge funds and other institutional investors Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation The new healthcare payment model is centered on the 120,000 children covered by Delaware's Medicaid program The new payor arrangement aligns the financial incentives that pay for healthcare with Nemours' aim to keep children healthy This partnership marks the first-ever pediatric global revenue budget model in the United States Unlike traditional arrangements in which providers earn more money for providing more medical services Nemours Children's will be incentivized to address both medical and non-medical drivers of children's health in an effort to avoid unnecessary medical expenses,” the press release noted “This program is a bold next step in Nemours whole child health model which considers both a child's medical needs and the social and community issues that impact their health and hospital care with health initiatives that impact all of Delaware's children including many who come from historically underserved communities This agreement builds on Nemours longstanding commitment to serving the children of Delaware and further establishes the First State as a leader in child health.” president and CEO of Nemours Children’s Health as stating that “We know that what happens in a child's home and community is critical in setting them up for lifelong health yet America's healthcare institutions are primarily paid for providing medical care Today's agreement creates the financial incentives for Nemours and the state of Delaware to align on what we all want: healthier kids who grow up to become healthier adults.” And it quoted Delaware Governor John Carney who stated that "Making sure our children are healthy and able to be successful is as important as anything we do I’m grateful for the hard work that the Department of Health and Social Services and Nemours Children's Health put into this effort to better support children across our state through innovative care,” Governor Carney said The press release noted that ,“Working in partnership with community support systems and local and state government agencies Nemours will coordinate access to the broader range of services needed to help children thrive and achieve optimal health Nemours' unique position as the only multistate multi-hospital pediatric system in the country will provide broadly applicable lessons in how different financing systems can improve overall child well-being and health in America.” chief population health officer at Nemours Children’s as stating that "This innovative global budget model will demonstrate how shifting to a 'pay for health' model can create the healthiest generations of Delaware's children Addressing social drivers through collaboration with parents communities and governmental agencies is foundational to the trajectory for healthy kids to become healthy adults." And it quoted Delaware Health and Social Services Secretary Josette Manning as stating that "I'm proud that the First State will yet again be first this time in bringing an innovative model to our state which will ensure the best health outcomes for Delaware's children I look forward to seeing the results of this effort in the years ahead." Healthcare Innovation Editor-in-Chief Mark Hagland interviewed Dr Moss to drill down on the announcement and get his perspective on what is being accomplished in launching this new payment model How did the journey towards this new payment model begin It starts at the core of who we are as an organization Nemours is in the business of creating health Our kids are every child in our service area and we should be accountable for creating health for every child And so we approached the state with that aspirational concept we were able to sign this MOU [memorandum of understanding.] And by the way I want to note that our colleagues and partners in the State of Delaware have worked extremely hard on this People talk about government moving at a slow pace but that was not my experience of this at all It’s based on the model of a global budget where we and the state come to an agreement on the value we mutually decide to put into a yearly spend for healthcare And then we’re accountable for providing the medical care; and if that ends up being a financial win for Nemours it’s actually a financial loss for us we’re learning together with the state during that three-year learning-model period our vision is that this is not Nemours and the state sitting on opposite sides of a negotiating table haggling over money; this is us all sitting on the same side of the table asking how can we create the best health for every child in Delaware This is the first-ever pediatric global budget model in the U.S We’ve learned a lot from the state of Maryland in particular and the total spend per person is different in childhood than in adulthood interventions outside the hospital to create health in childhood And now that we’ve agreed to do the model we’re sitting down with our partners at the state to figure out what the funds flow looks like Health includes more than just medical care And we’re working through now those dollars will flow And those are complicated to marry those issues to medical care in children What is the timeframe for working out the details of the model in the context of the three-year initiation phase The intent isn’t to hold feet to the fire for results because we’re learning what results will look like We’re really in a learning mode over those first three years But the state and Nemours have extended some considerable amount of trust to make this happen And if we didn’t both believe that we were really mutual partners The state of Marland’s global budget is purely about medical costs paramount foundation of our model is child health You must have done some analytics on this before you moved forward with the plan and we’ve engaged some very sophisticated actuarial firms You’ll be investing very early on in a child’s life in terms of preventive health and wellness we’re trying to treat disease with compassion we’re really building out the road ahead of us That is way outside a budget cycle or a political election cycle My answer to that is that there are enough modest short-term financial wins in terms of reducing acute-care stays and ED visits—there’s enough bang there early to demonstrate that this is viable financially But those short-term wins pale in comparison to a longer-term reduction in the incidence of cancer I still remember your telling me the vivid story a few years ago of a patient named Wendell because of lack of access to a safe playground space and more than a million dollars’ worth of medical care providing a safe playground space near his public housing would have been so inexpensive and so effective His care cost multiple millions of dollars And he endured a nightmare experience because of the injury in working out this new payment model with the state of Delaware you were thinking of Wendell and other kids like him to ask what the real problem was; and often the real problem was a child who grew up without the resources for play supervision Or a child who got the worst case of RSV in town and ended up in the ICU So we want to be creating health in the first place which will of course mean less medical care needed down the road There will always be kids who need heart transplants and chemotherapy and we’ll always absolutely be there for them; we’re there on both sides of the equation you’re not trying to get rid of yourselves but there will always be disease out there and we will always be there to care for children with illness We need to create greater health to insulate people from things like Medicaid rollbacks and our payment system does have a lot of flaws But what we’re talking about today is even a level above that Regardless of your health insurance coverage incentivizes the opposite of health; it incentivizes the maximal amount of care delivery as possible We should fix the vagaries of payment systems; but what we really need to do is to change the financial incentives of providers Analysts from the Medicare program just announced last month that the healthcare system experienced 10.4 percent hospital inflation over the last year and at the risk of sounding like a broken record Every fiber of our system incentivizes volume and complexity And this model we’re talking about today Is there anything else you’d like to add Three things I want people to understand about this model This is an agreement to make our state’s children the healthiest in the country we’re focusing on every child in our service area it’s highly significant that this is a true partnership between our health system and the state Boothbay Fund Management LLC purchased a new position in shares of DuPont de Nemours, Inc. (NYSE:DD - Free Report) during the 4th quarter according to the company in its most recent 13F filing with the Securities and Exchange Commission The institutional investor purchased 4,614 shares of the basic materials company's stock Other hedge funds and other institutional investors have also made changes to their positions in the company Tidal Investments LLC raised its holdings in shares of DuPont de Nemours by 10.7% in the 3rd quarter Tidal Investments LLC now owns 32,061 shares of the basic materials company's stock valued at $2,857,000 after purchasing an additional 3,096 shares in the last quarter Synovus Financial Corp lifted its holdings in DuPont de Nemours by 2.5% during the 3rd quarter Synovus Financial Corp now owns 36,538 shares of the basic materials company's stock worth $3,256,000 after buying an additional 905 shares during the last quarter boosted its position in shares of DuPont de Nemours by 9.8% during the 3rd quarter now owns 6,410,485 shares of the basic materials company's stock worth $556,751,000 after acquiring an additional 570,703 shares in the last quarter Garden State Investment Advisory Services LLC purchased a new position in shares of DuPont de Nemours in the 3rd quarter valued at about $203,000 raised its position in shares of DuPont de Nemours by 4.6% during the 3rd quarter now owns 490,704 shares of the basic materials company's stock worth $43,727,000 after acquiring an additional 21,435 shares in the last quarter Hedge funds and other institutional investors own 73.96% of the company's stock A number of equities analysts recently issued reports on the company KeyCorp upped their price target on DuPont de Nemours from $81.00 to $85.00 and gave the company an "overweight" rating in a report on Monday UBS Group cut their price target on shares of DuPont de Nemours from $103.00 to $75.00 and set a "buy" rating on the stock in a research note on Tuesday Wolfe Research upgraded shares of DuPont de Nemours from a "peer perform" rating to an "outperform" rating and set a $91.00 price objective for the company in a research note on Friday Citigroup dropped their price objective on DuPont de Nemours from $95.00 to $74.00 and set a "buy" rating on the stock in a report on Tuesday Wells Fargo & Company reduced their target price on DuPont de Nemours from $105.00 to $81.00 and set an "overweight" rating for the company in a report on Wednesday Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock the stock has a consensus rating of "Moderate Buy" and a consensus target price of $85.07 Check Out Our Latest Stock Report on DuPont de Nemours DD traded down $1.83 during trading on Monday has a twelve month low of $53.77 and a twelve month high of $90.06 The firm has a market capitalization of $27.38 billion The company's 50-day moving average price is $69.81 and its 200 day moving average price is $76.59 DuPont de Nemours (NYSE:DD - Get Free Report) last posted its quarterly earnings results on Friday The basic materials company reported $1.03 EPS for the quarter beating the consensus estimate of $0.95 by $0.08 The company's quarterly revenue was up 4.6% compared to the same quarter last year equities research analysts forecast that DuPont de Nemours will post 4.38 EPS for the current fiscal year This represents a $1.64 annualized dividend and a dividend yield of 2.51% DuPont de Nemours's dividend payout ratio is presently -863.16% Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets Download the report now to identify top dividend payers and avoid common yield traps DuPont de Nemours (NYSE:DD - Get Free Report) will likely be posting its Q1 quarterly earnings results before the market opens on Friday Analysts expect DuPont de Nemours to post earnings of $0.95 per share and revenue of $3.05 billion for the quarter DuPont de Nemours has set its FY 2025 guidance at 4.300-4.400 EPS and its Q2 2025 guidance at 1.050-1.050 EPS the business posted $0.79 earnings per share The company's revenue was up 4.6% on a year-over-year basis analysts expect DuPont de Nemours to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year Shares of NYSE DD traded down $1.16 during mid-day trading on Monday The stock had a trading volume of 901,667 shares compared to its average volume of 3,008,073 The firm has a market cap of $27.66 billion The business has a 50 day moving average price of $69.81 and a two-hundred day moving average price of $76.59 DuPont de Nemours has a 1 year low of $53.77 and a 1 year high of $90.06 The company also recently disclosed a quarterly dividend This represents a $1.64 annualized dividend and a dividend yield of 2.48% DuPont de Nemours's dividend payout ratio (DPR) is -863.16% An institutional investor recently raised its position in DuPont de Nemours stock. Brighton Jones LLC lifted its position in DuPont de Nemours, Inc. (NYSE:DD - Free Report) by 19.6% during the 4th quarter according to the company in its most recent Form 13F filing with the SEC The institutional investor owned 5,012 shares of the basic materials company's stock after buying an additional 822 shares during the period 73.96% of the stock is owned by institutional investors A number of research analysts recently issued reports on DD shares Citigroup reduced their price target on DuPont de Nemours from $95.00 to $74.00 and set a "buy" rating on the stock in a report on Tuesday Morgan Stanley reduced their target price on DuPont de Nemours from $94.00 to $80.00 and set an "equal weight" rating on the stock in a research note on Monday Wells Fargo & Company dropped their price target on DuPont de Nemours from $105.00 to $81.00 and set an "overweight" rating for the company in a research note on Wednesday Wolfe Research raised shares of DuPont de Nemours from a "peer perform" rating to an "outperform" rating and set a $91.00 price objective on the stock in a research report on Friday BMO Capital Markets raised their target price on shares of DuPont de Nemours from $105.00 to $112.00 and gave the stock an "outperform" rating in a research report on Thursday Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock the stock has a consensus rating of "Moderate Buy" and an average target price of $85.07 Get Our Latest Analysis on DuPont de Nemours It's the hottest energy sector of the year and BWX Technologies were all up more than 40% in 2024 The biggest market moves could still be ahead of us and there are seven nuclear energy stocks that could rise much higher in the next several months Nemours Children’s Health and the State of Delaware launch a new payment model for kids in the state’s Medicaid program This new model has payment incentives based on Nemours being able to help children stay healthy and avoid hospital treatment instead of reimbursing Nemours for treating children Kara Walker is Nemours Chief Population Health Officer "This payment model is centered around the 120,000 children who are covered by Delaware's Medicaid and it helps to actually reorient the way that Nemours is paid It helps to focus on being paid for creating health This is truly a first ever pediatric global revenue budget model in the entire country," said Walker This arrangement incentivizes Nemours to address not only medical drivers of children’s health but also non-medical drivers in an effort to avoid unnecessary medical expenses This latest step in Nemours whole child health model helps to consider both a child’s medical needs and the social and community issues that impact their health She says this moves away from the traditional model where providers earn more money for providing more medical services “Other arrangements allow doctors to earn more and hospitals to earn more for providing more services,” said Walker “We are really trying to go upstream and focus on prevention what is necessary to keep kids out of the hospital." Nemours and the state are touting this agreement as a milestone in creating the healthiest generations of children This agreement comes after several years of discussions between Nemours Agreement marks significant milestone in creating the healthiest generations of children 2025 /PRNewswire/ -- Nemours Children's Health and the State of Delaware today announced an agreement to create a transformational new effort aimed at making Delaware's children the healthiest in the nation Nemours Children's will be incentivized to address both medical and non-medical drivers of children's health in an effort to avoid unnecessary medical expenses This program is a bold next step in Nemours whole child health model This agreement builds on Nemours longstanding commitment to serving the children of Delaware and further establishes the First State as a leader in child health "We know that what happens in a child's home Today's agreement creates the financial incentives for Nemours and the state of Delaware to align on what we all want: healthier kids who grow up to become healthier adults," said R President and CEO of Nemours Children's Health "Nemours will continue to provide world-class medical care while also coordinating with community organizations that address non-medical issues like nutrition "Making sure our children are healthy and able to be successful is as important as anything we do," said Governor John Carney "I'm grateful for the hard work that the Department of Health and Social Services and Nemours Children's Health put into this effort to better support children across our state through innovative care." Working in partnership with community support systems and local and state government agencies multi-hospital pediatric system in the country will provide broadly applicable lessons in how different financing systems can improve overall child well-being and health in America "This innovative global budget model will demonstrate how shifting to a 'pay for health' model can create the healthiest generations of Delaware's children," said Kara Odom Walker Chief Population Health Officer at Nemours Children's "Addressing social drivers through collaboration with parents "I'm proud that the First State will yet again be first this time in bringing an innovative model to our state which will ensure the best health outcomes for Delaware's children," said Delaware Health and Social Services Secretary Josette Manning "I look forward to seeing the results of this effort in the years ahead." The global budget model is the culmination of several years of discussions between Nemours the State and community partners about their shared priority of addressing the health needs of children in Delaware Nemours Children's Health is one of the nation's largest multistate pediatric health systems which includes two freestanding children's hospitals and a network of more than 70 primary and specialty care practices Nemours Children's seeks to transform the health of children by adopting a holistic health model that utilizes innovative while also addressing children's needs well beyond medicine award-winning pediatric medicine podcast Well Beyond Medicine Nemours underscores that commitment by featuring the people programs and partnerships addressing whole child health Nemours Children's also powers the world's most-visited website for information on the health of children and teens established through the legacy and philanthropy of Alfred I Nemours Children's Health today opened the Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders (Moseley Foundation Institute) Financial Technology Financial Technology duPont Institute building underscore Nemours Children's continued commitment to Delaware andthe health of its children 2024 /PRNewswire/ -- Nemours Children's Health announced several significant investments today including plans for a groundbreaking Maternal and Fetal Health Program and the revitalization of the historic Institute building on the Alfred I Investments in these projects will total $130 million in 2025—the largest one-year capital investment in Delaware in Nemours history "We are proud to announce our next phase of growth as the largest provider of children's health in Delaware," said R "Every dollar earned by Nemours is invested back into our mission These capital investments build on Alfred I and our strong financial position helps further Nemours Children's vision to create the healthiest generations of children in Delaware and beyond." "Nemours has deep roots in Delaware and an enduring commitment to its children and families," said Mark R "We will continue working with our partners in state and local government and community organizations to go well beyond medicine for Delaware's kids." Nemours will expand its Advanced Delivery Program at Nemours Children's Hospital state-of-the-art Maternal and Fetal Health Program Nemours sees transformational potential to elevate the health of children and families in Delaware through improved diagnostics and cutting-edge maternal-fetal therapies," said Kate Deans Nemours plans to expand the Advanced Delivery Program at Nemours Children's Hospital Delaware to include four new labor and delivery birthing suites eight new antepartum and postpartum rooms and three operating rooms that can be used for both fetal and maternal care "It is critical that we provide these services to Delawareans who would otherwise need to leave our state to receive this level of care This places unnecessary burden on families to travel away from their other children and their support networks We aim to provide the highest level of quaternary care to these families right here in Delaware." Nemours commitment to a more comprehensive maternal-fetal health strategy has attracted distinguished specialists to expand its in utero diagnostic and surgical interventions Three highly accomplished maternal-fetal medicine specialists will be joining the Nemours team over the next 15 months: Eric P Bergh will collaborate closely with the Advanced Delivery Program and Delaware executive team to expand Nemours existing care portfolio Paidas Teefey will work with the Florida maternal-fetal medicine teams to offer highly specialized care in Florida "We are laying the foundation here in Delaware to become the nation's first multi-hospital multistate children's health system providing fetal diagnosis and therapy—and one of the country's largest fetal medicine programs," said Dr Delaware's only Level IV Neonatal Intensive Care Unit (NICU) will be expanding in 2025 the NICU will house 45 beds as a contiguous unit With the support of a generous donation by the Lisa Dean Moseley Foundation Nemours plans to open the Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders in early 2025 the first phase of the Moseley Foundation Institute will feature 24 inpatient beds reflecting a family-centered state-of-the-art design that overlooks the beautiful gardens of the Nemours Estate to promote healing and recovery With further investment from Nemours with support by the Moseley Foundation the Moseley Foundation Institute will also feature a 19,000-square-foot outpatient Day Hospital and Infusion Center—more than quadrupling its current size In addition to providing a patient-centered care experience the outpatient area is designed to foster clinical trial participation to advance the treatment of children with cancer Nemours has also named two distinguished new leaders to advance its Cardiology practice: Aaron W will become chair of Cardiovascular Medicine chief of Cardiothoracic Surgery and executive director of the Nemours Children's Cardiac Center in the Delaware Valley will be chief of Cardiac Anesthesia and co-director of the Nemours Cardiac Center Revitalization of historic duPont Institute building Nemours will continue to revitalize the original Alfred I duPont Institute on its Wilmington campus as a state-of-the-art administrative office building while paying homage to its origin as the founding A.I The Institute opened in 1940 as a children's orthopedic hospital and was the original health care structure funded by the Nemours Foundation the first major hospital expansion on the Nemours Children's Hospital The 450,000-square-foot expansion of Nemours/Alfred I duPont Institute will preserve the building's core architectural elements and maintain a direct connection to clinic spaces in the duPont Pavilion state-of-the-art Simulation Center to provide hands-on interactive pediatric simulation experiences in a safe This collaborative teaching and education enhance technical skills for care providers across the organization improving the quality of care and leading to better outcomes Nemours has grown to become one of the nation's most respected multistate children's health systems," said Marcantano "Our commitment to Delaware's families has only grown over the years and that deep connection and partnership continues to advance the health of children in the First State." The Nemours Foundation, established through the legacy and philanthropy of Alfred I. duPont, provides pediatric clinical care, research, education, advocacy, and prevention programs to the children, families and communities it serves. For more information, visit Nemours.org Banking & Financial Services Venture Capital The eight-figure funding supports redevelopment of the center to create a modernized hub for health care 2025 /PRNewswire/ -- As part of its bold vision to create the healthiest generations of children Nemours Children's Health is lending community impact funds toward the redevelopment of the historic Kingswood Community Center in Wilmington's Riverside neighborhood The funds will be pivotal in bringing health care and other services and resources to children and families in the area through new programs and the completion of a state-of-the-art facility "Achieving our vision starts with community-centered partnerships that address the conditions in which kids grow "In addition to providing exceptional medical care Nemours recognizes that a child's community has a tremendous impact on their health The Kingswood Community Center's holistic approach aligns with this philosophy lifelong health impacts for kids and families." The Kingswood community impact loan advances Nemours Children's Health's goals to create long-term sustainable health improvements that advance community change and improve health and well-being in the communities it serves Nemours has long provided medical services in Riverside and the fact that many Kingswood community members are also Nemours Children's patients helped spark this unique connection The new facility will provide expanded services such as early learning and community programs that help children grow into healthy adults Nemours Children's also plans to lease space in the facility to increase access to high-quality pediatric clinical care for local families.   "This partnership with Nemours Children's Health is a testament to what's possible when we come together with a shared vision for a stronger healthier community," said Logan Herring Sr. Kingswood Community Center and The WRK Group we are building a future where every child This is not just about health care—it's about hope and building the foundation for generations to succeed."  "Riverside isn't just where I work—it's the neighborhood that provided refuge for my family and me during very challenging times I have witnessed the power of community-driven change and I know that when organizations like Nemours Children's Health invest in our neighborhoods it creates lasting impact," said Kingswood Community Center Board Chair James "Ray" Rhodes who is also STEM Hub/Community Engagement director at Eastside Charter School "This partnership ensures that families have access to the quality care they need and for the future we're building together." Nemours is providing bridge financing to close a critical funding gap and accelerate construction and programming at the center The revitalized Kingswood Community Center which has been providing critical resources in the community since the 1940s will offer a comprehensive range of services and integrated pediatric and adult health care "By investing in community impact strategies we help improve the way children grow and learn in the communities we serve in long-term reaping benefits beyond improved child health," said Jim Hunt Chair of The Nemours Foundation Board of Directors "This innovative approach underscores Nemours Children's Health's commitment to tackling the root causes of health for children in paradigm-shifting ways." The Kingswood project was made possible through a blend of community-focused financing tools designed to spur investments in neighborhoods like Wilmington's Riverside The Nemours Foundation, established through the legacy and philanthropy of Alfred I. duPont, provides pediatric clinical care, research, education, advocacy, and prevention programs to the children, families and communities it serves. For more information, visit Nemours.org one of the nation's largest multistate pediatric health systems 2025 /PRNewswire/ -- Nemours Children's Health as the new Executive Vice President and Chief Financial Officer (CFO) ensuring Nemours Children's maintains its financial strength and stability as the organization continues its commitment to delivering the highest quality care and addressing all of the factors that impact child health Samms brings more than 25 years of progressive experience in large healthcare systems he served as Senior Vice President and Chief Financial Officer at St His executive experience includes budgeting "Caswell's leadership will help keep our financial foundation strong enabling us to achieve our vision of creating the healthiest generations of children," said R and he shares our commitment to helping children reach their full potential." Samms holds a Bachelor of Science in Accounting from Virginia State University and an Masters of Business Administration (MBA) from Regis University He is Lean Six Sigma Green Belt certified and is a member of the American College of Healthcare Executives and the Healthcare Financial Management Association Becker's Hospital Review named him among its Rising Stars and Diversity MBA included him in its "Top 100 Under 50 Executive Leaders." About Nemours Children's HealthNemours Children's Health is one of the nation's largest multistate pediatric health systems Children who fall behind in reading don't just struggle in school—they are also at higher risk for chronic illness and mental health issues later in.. As part of its bold vision to create the healthiest generations of children Nemours Children's Health is lending community impact funds toward the.. Personnel Announcements Please press and hold the button until it turns completely green If you believe this is an error, please contact our support team 147.45.197.102 : 9830bd54-95d9-46ea-b39a-f1762d60 Valued at a market cap of $26.4 billion, DuPont de Nemours, Inc. (DD) is a multi-industrial company that provides technology-based materials and solutions Delaware-based company operates through Electronics & Industrial the company has surpassed Wall Street's bottom-line estimates in each of the past four quarters For the full fiscal 2025, analysts forecast DuPont to report an adjusted EPS of $4.25, marking a 4.4% increase from $4.07 reported in fiscal 2024 its earnings are expected to further grow 8% year-over-year to $4.59 per share DuPont de Nemours’ stock prices rose 6.9% following the release of its strong Q4 2024 results on Feb The company posted quarterly revenue of $3.1 billion which led to 10% organic growth in the Electronics & Industrial segment along with continued momentum in water markets resulting in 6% organic growth in the Water & Protection segment marking a 29.9% increase from the prior-year quarter and surpassing the consensus estimate by 15.3% DD maintains its positive momentum and projects net sales to range between $12.8 billion and $12.9 billion with adjusted EPS to be in the range of $4.30 - $4.40 Furthermore, analysts' consensus view on DD stock is strongly optimistic opinions include 11 "Strong Buys," one "Moderate Buy," and four "Holds.” Its mean price target of $85.20 suggests a 29% upside potential from current price levels On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here Investment highlights Nemours commitment to children's health 2024 /PRNewswire/ -- As part of its overall commitment to pediatric health Nemours Children's Health will invest $300 million in Central Florida over the next four years to meet growing needs for highest-quality pediatric care Experience the full interactive Multichannel News Release here: https://www.multivu.com/nemours/9307751-en-nemours-childrens-health-florida-expansion "This expansion is a critical step in achieving our vision of bringing world-class children's care to Florida Our journey to become a nationally ranked children's hospital here will give us the capacity to support even more families regionally As part of Nemours commitment to providing optimal health to children in Delaware the plan consists of three new buildings on the Nemours Children's Hospital "While Nemours has offered world-class pediatric healthcare services to children in the Delaware Valley for years this significantly deepens our commitment to Central Florida strengthening our position as the state's leading children's healthcare system," said Martha McGill President of the Central Florida Region for Nemours Children's "This investment is designed to care for more children It also directly aligns with our broader mission to reimagine children's health to keep them well beyond medicine." As the fastest growing state in the nation Florida faces an increased need for pediatric services Nemours currently serves over 300,000 children and teens in the state the pediatric population of 1 million is expected to grow by nearly 5% over the next five years Nemours Orlando expansion will better support both immediate capacity needs and future growth to meet the needs of patients and families Nemours has more than 50 locations in the state and employs Florida's largest and most well-distributed team of pediatric specialists "The health of any community starts with its children and we intend to play a leading role in creating the healthiest generations of Americans through our multistate pediatric health system," said Dr "We're thrilled that through careful stewardship and commitment we can make these critical investments across our system to set up patients families and communities for the best possible health outcomes." Nemours Children's Health is operated by the Nemours Foundation formed from the legacy and philanthropy of Alfred I This investment in Central Florida honors duPont's legacy of stewardship with Nemours strong financial position enabling it to invest in new and expanded facilities across its multistate pediatric health system to further its mission The Nemours Foundation, established through the legacy and philanthropy of Alfred I. duPont, provides pediatric clinical care, research, education, advocacy, and prevention programs to the children, families and communities it serves. For more information, visit Nemours.org Corporate Expansion DuPont de Nemours (NYSE:DD - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Friday Analysts expect the company to announce earnings of $0.96 per share and revenue of $3.05 billion for the quarter DuPont de Nemours has set its Q1 2025 guidance at 0.950-0.950 EPS and its FY 2025 guidance at 4.300-4.400 EPS DuPont de Nemours (NYSE:DD - Get Free Report) last posted its earnings results on Tuesday The basic materials company reported $1.13 earnings per share (EPS) for the quarter beating analysts' consensus estimates of $0.98 by $0.15 DD stock traded up $0.17 during midday trading on Wednesday 2,934,450 shares of the company's stock traded hands compared to its average volume of 2,419,606 The company has a 50-day simple moving average of $70.42 and a two-hundred day simple moving average of $76.98 a current ratio of 1.33 and a debt-to-equity ratio of 0.22 DuPont de Nemours has a 1-year low of $53.77 and a 1-year high of $90.06 The company has a market cap of $27.63 billion The firm also recently announced a quarterly dividend This represents a $1.64 dividend on an annualized basis and a dividend yield of 2.48% DuPont de Nemours's dividend payout ratio (DPR) is presently 98.20% A hedge fund recently raised its stake in DuPont de Nemours stock. Brighton Jones LLC lifted its stake in shares of DuPont de Nemours, Inc. (NYSE:DD - Free Report) by 19.6% in the 4th quarter according to its most recent Form 13F filing with the Securities & Exchange Commission The institutional investor owned 5,012 shares of the basic materials company's stock after acquiring an additional 822 shares during the period Brighton Jones LLC's holdings in DuPont de Nemours were worth $382,000 at the end of the most recent quarter Several equities research analysts have weighed in on the stock Wells Fargo & Company lowered their price objective on shares of DuPont de Nemours from $105.00 to $81.00 and set an "overweight" rating for the company in a research report on Wednesday UBS Group reduced their price objective on DuPont de Nemours from $103.00 to $75.00 and set a "buy" rating on the stock in a report on Tuesday BMO Capital Markets lifted their target price on DuPont de Nemours from $105.00 to $112.00 and gave the company an "outperform" rating in a research note on Thursday KeyCorp raised DuPont de Nemours from a "sector weight" rating to an "overweight" rating and set a $81.00 price target on the stock in a research note on Monday Bank of America upgraded DuPont de Nemours from an "underperform" rating to a "neutral" rating and decreased their price target for the company from $80.00 to $75.00 in a report on Tuesday the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.79 A new study finds a significant need for more resources in a lesser-known area of childhood cancer treatment The study conducted by researchers at Nemours Children’s Health finds children’s oncology treatment facilities need more resources to provide support for patients and their families Enterprise Director of the Nemours Center for Healthcare Delivery Science psychologists and other specialists provide valuable psychosocial support “It's a broader kind of concept of both psychological aspects "As well as social - as in what is their world like outside the hospital What we talk about in terms of social determinants of health.” The vast majority of the 129 programs Kazak’s team surveyed had some psychosocial staffing in place But she says the larger problem is the types of staff Over 90% of programs had social workers and child life specialists but the numbers of psychologists and psychiatrists are more bleak Kazak says the data show less than 70% of facilities had psychologists with neuropsychologists in 39%; and psychiatrists in just 15% Neuropsychologists play a role in care because some treatments for cancer can cause neurological complications “There are a lot of treatments for childhood cancer that have the potential to be neurotoxic to impact the brain in terms of performance in school which is often called in if there's questions about whether or not the use of medications might be helpful.” funded by the Andrew McDonough B+ Foundation is a follow-up to one conducted several years ago after standards for psychosocial care were established in 2015 One bright spot is the availability of Spanish-speaking mental health staff in pediatric oncology programs increased from about 29% in 2016 to about 39% in 2023 the leaders of Nemours Children’s Health announced that the health system will be making investments totaling $430M in its Delaware Valley and Central Florida operations Nemours will be spending $130 million in 2025 on three projects: a groundbreaking new Maternal & Fetal Health Program to be led by 3 nationally recognized specialists with new birthing suites and expanded space for maternal and fetal surgery and care; expansion of its neonatology and cardiology programs; and revitalization of the Alfred I duPont Institute – Nemours’ original hospital building Nemours will invest $300M over the next four years in new and expanded facilities to meet the area's growing needs The three areas of focus will be: a 110,000-square-foot expansion of its hospital; a new 75,000-square-foot facility for orthopedic and sports medicine; and a new 75,000-square-foot administrative building Following the announcement in December of the group of investments Moss spoke with Healthcare Innovation Editor-in-Chief Mark Hagland about the investments and about the broader context of the Nemours Children’s organization’s commitment to its service areas and communities can you share about the origin of this set of investments and what it means more broadly for the organization but I want people to know that Nemours is in the business of creating health We think we have an important role to play in the way that America conceptualizes health of children and delivers healthcare to children This investment is on the side of care delivery Some people have misinterpreted what I’ve said in the past but it’s an “and,” not an “or.” So while we’re doing exciting things for children outside the hospital we’re still investing in care in the hospital and that’s what these investments are Can you discuss the sources of the funding judicious management on the part of our teams as we’ve anticipated the need for growth We’ve oriented our financial performance for years And we’ve been supplemented by generous gifts including from the Lisa Dean Moseley Foundation and we’re very proud that we’ve been able to manage our internal resources successfully even during a time of financial challenges We all know that this is a difficult time in terms of reimbursement of all types How are you managing in the current environment It is a challenging financial time for healthcare entities and particularly for this country’s children’s hospitals But we’ve made some very hard and deliberate decisions to make sure that we can continue to perform adequately We’re a not-for-profit entity; we’re not in business to make money we’re in business to enhance the health of children we have to invest intelligently in the health of children and we’re doing things in our major markets We’re cognizant that in order to deliver health Is this a more difficult time than two years ago There are a variety of challenges that we all face I’ll say that fundamentally in the United States all children’s hospitals are fundamentally under-reimbursed and live on a shoestring all the time and to the extent that I can play a role and continue to advocate for sustainability facing the Medicaid challenges we face I think it’s important for the American people to understand—a lot of people don’t realize this—over half of all children in the US get their healthcare funded by Medicaid and Medicaid in the vast majority of cases We have a big challenge with underinsurance of kids through the Medicaid program and that’s an important thing to discuss What will you be able to do with these investments we’re developing what will be one of the biggest programs for mothers with children born with congenital anomalies And we’re turning the original DuPont Institute back into an office build as it was from the 1940s How should leaders be strategizing ahead for the next few years The major trend in children’s care over the coming decade is that we’re doing more and more on an outpatient basis The children’s hospital of the future is going to be a giant ICU So we’re one of the leading organizations in the country building a hospital-at-home program for children we’re responding to increased market demand We’re actually putting less of a percentage of kids in beds but our market share is actually increasing both in the Delaware Valley and in central Florida Tertiary and quaternary care will still be needed for the sickest of the kids Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that teaches emotional management and how to maintain healthy relationships through the acceptance of the patient’s experience and the need for change; it’s particularly effective for those who experience intense emotions and engage in self-destructive behaviors It’s also particularly effective with one population currently in dire need of behavioral health care: teenagers Nemours Children’s Hospital in Delaware offers one of two DBT programs in the state and the skills they need to improve their mental health group skills training and other support strategies teens who have undergone DBT have reduced self-harm and suicidal behavior as well as emotional management and enhanced relationships Read more about the program here along with the Phillie Phanatic and Phillies Ballgirls made a special trip to Nemours Children’s Hospital Delaware to get everyone revved up for Sunday’s Childhood Cancer Awareness Night presented by Nemours Children’s Health at Citizens Bank Park Rojas visited the hospital’s oncology unit where he took photos and signed autographs for children receiving care as well as thanked hospital staff for all they did for families battling cancer A Phillies Pep Rally hosted by Nemours was also held in the hospital’s atrium and photo opportunities with the Phillie Phanatic and Phillies Ballgirls Among those taking part in the festivities (and hiding cotton candy from the Phanatic!) was cancer warrior Eric Newton (14 who will have the honor of throwing a ceremonial first pitch at Sunday’s game Nemours Children's Health will invest $130 million next year to expand its Advanced Delivery Program and Neonatal Intensive Care Unit Nemours said in an announcement Tuesday that it will be the largest one-year capital investment in Delaware in their history "These capital investments build on Alfred I and our strong financial position helps further Nemours Children’s vision to create the healthiest generations of children in Delaware and beyond," said Dr president and CEO of Nemours Children's Health Nemours already provides support and care during pregnancy including specialists available for babies in need of intensive care the Maternal and Fetal Health Program will add four new labor and delivery birthing suites and three operating rooms that can be used for both fetal and maternal care Fourteen new inpatient rooms will also be added to Nemours' NICU “It is critical that we provide these services to Delawareans who would otherwise need to leave our state to receive this level of care," said Dr surgeon-in-chief at Nemours Children’s Health in the Delaware Valley "This places unnecessary burden on families to travel away from their other children and their support networks." The hospital also plans to collaborate with the maternal-fetal medicine teams at Nemours' Florida locations to bring similar levels of care duPont Institute has been part of Nemours' Rockland campus since it was founded in 1940 Originally used as a children's orthopedic hospital the historic building has since become a staple of the hospital system in Delaware which are expected to be completed by mid-2026 will "preserve the building’s core architectural elements," according to Nemours The institute will maintain a direct connection to the clinic spaces while adding a Simulation Center to provide hands-on The space will primarily be used as an administrative office building but will still "(pay) homage to its origin." Next year will also mark the opening of the Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders which will have 24 inpatient beds to reflect a "family-centered state-of-the-art design." Nemours hosted a groundbreaking ceremony for the institute on May 20 following a $78 million donation from the Wilmington-based nonprofit The foundation funds research and clinical programs nationwide to support medical and scientific progress Further investment from Nemours and the Lisa Dean Mosley Foundation will add a 19,000-square-foot outpatient day hospital and infusion center The institute also aims to foster participation in clinical trials to advance treatment for children with blood disorders MORE: Former researcher at Nemours, UD manipulated data, leading to medical article retractions The Jaguars and Nemours Children's Health partnered together to surprise the children at Episcopal Children's Services Early Head Start Westside with a special 'Jaxson's Jump' Literacy Locker Room Students enjoyed an exclusive book reading from the ROAR as well as Nemours and Jaguars giveaway items — Jaxon's Big Jump Literacy Locker Room at Episcopal Children's Services Early Head Start Westside on March 4 The Jaguars and the Florida Lottery kicked off Read Across America Week at River City Science Academy Jaxson de Ville and the ROAR surprised students with an exclusive reading giveaways and a free book for them to add to their personal libraries The Jacksonville Jaguars and EverBank teamed up for another Financial Literacy Camp on Feb 18th Jaguars Legends Mike Hollis and David Garrard joined close to 500 Duval County Public School students and the Boys and Girls Clubs of Northeast Florida for two camps focused on financial literacy Participants learned about the importance of saving as it relates to football and for their future ROAR cheerleaders and mascot Jaxson DeVille worked through food donations with Feeding Northeast Florida sorting 3,667 pounds of food and 3,056 meals combined Jaxson de Ville and Jaguars Legend Kevin Hardy celebrated Duval County Public Schools Literacy Week at S.P Livingston and DePaul School with Literacy Locker Room visits thanks to the partnership with JEA The DePaul School provides students with dyslexia in grades second through eighth the proper tools and curriculum to succeed in the classroom Students received an exclusive reading of Jaxson's Big Jump and received Jaguars swag to celebrate the importance of reading and get additions to their libraries Cornerback Tyson Campbell joined Jaxson De Ville and the ROAR at Beauclerc Elementary for a special read of Papa's Mechanical Fish with the goal of expanding literacy education to our local schools 🍎 Safety Daniel Thomas and Linebacker Chad Muma read Jaxson's new book alongside the ROAR and Jaxson De Ville himself at Andrew Robinson school as part of our Literacy Locker Room program Reading matters 📚 The Jaguars teamed up with Gallagher for a Literacy Locker Room at the John Love Early Learning Center and The Roar joined to read to the students and distribute hundreds of books and Jags swag Jaxson launched a book 🐆 Earlier this week patients at Nemours Children's Clinic were given a sneak peek of the book with a special reading by Jaguars Legend K Josh Scobee and received a backpack with an autographed book from Jaxson and photo opportunities with the mascot and THE ROAR Nemours will also host an upcoming Literacy Locker Room (Jaxson's Version) this fall Thank you to everyone who came out to our Monday Night Football watch party at the Bank For our 2024 home opener against the Cleveland Browns Jaguars season ticket members got to attend a members only pregame tailgate with an opportunity to hear from GM Trent Baalke The Jacksonville Jaguars Foundation's 2nd Annual Community Day presented by Florida Blue positively impacts thousands of local children and military personnel through care package assembly in the Flex Field at Daily's Place Regency Centers and Tito's Vodka assembled care packages for Feeding Northeast Florida lunch and photo opportunities with Jaxson de Ville and Jaguars Legends David Garrard and Kevin Hardy The Jaguars hosted an exclusive STM only day at training camp Check out photos from this event and thank you for being the backbone of our fan base The Florida Supreme Court has declined to take up a dispute about whether Delaware has been shortchanged in the distribution of money from a charitable trust tied to the late industrialist Alfred I The Supreme Court issued three orders last week denying requests by the Florida Attorney General’s Office and two other parties to review a decision by the 5th District Court of Appeal The appeals court said Delaware Attorney General Kathleen Jennings can pursue a lawsuit alleging a breach on a 50 percent limit on distribution of money to states other than Delaware The appeals court opinion last year was part of decades of legal wrangling about a duPont charitable trust and the nonprofit Nemours Foundation which was created with money from the trust and provides pediatric medical care in Florida and other states duPont included in his will and in the trust documents specific clear direction that the children and elderly of Delaware were to receive priority and were to be taken care of before expending trust funds on children or elderly residing elsewhere.” a lawsuit filed in the late 1970s led to a settlement that limited how much of the trust money distributed each year to Nemours could be spent outside Delaware Then-Delaware Attorney General Matthew Denn filed a lawsuit in 2017 against the trust and Nemours Foundation alleging breach of contract and breach of trust duties Florida intervened in the case on the side of the trust and foundation Along with the Florida Attorney General’s Office the trust and foundation also asked the Supreme Court to review the case the Supreme Court did not explain its decision for declining to take up the case (Editor's note: This story has been updated to include comment from Nemours Children's Health and reflect where the retracted articles were originally published.) A former researcher at Nemours Children's Health in Delaware has admitted to falsifying data leading to the retraction of two published scientific articles affiliated with Nemours and the University of Delaware According to the retraction notices published in JVS-Vascular Science and Oncotarget Valerie Sampson admitted to manipulating samples to show the desired results The studies' co-authors were not aware of the misconduct “I take sole responsibility for the errors and the incorrect reporting of data," Sampson said in a statement in the retraction notice of one article "These actions were unknown to all co-authors of this study I apologize to the members of staff of Oncotarget the reviewers who provided the reviews for the manuscripts all who were involved in the publication of this manuscript and anyone who is impacted by my actions.” The retraction also stated that Nemours launched an investigation into Sampson and ultimately concluded that the article needed to be retracted "We have alerted journals regarding articles authored by her for which we identified potential concerns and those journals are proceeding with their investigations," Nemours said in an emailed statement "We take any misconduct very seriously and are committed to reporting and working with all necessary parties when concerns about research integrity arise." Sampson's LinkedIn profile states she worked as a full-time research scientist at Nemours for over 16 years She also worked as an affiliated scientist at UD from 2016 to 2022 before becoming a scientist at Philadelphia-based cell and gene therapy developer WuXi Advanced Therapies HEALTH CARE NEWS: Delaware's hospital review board, at center of lawsuit, sees first members approved She reported her employment status as unemployed since October 2023 UD did not respond to a request for comment Here’s a look at some of the amazing moments captured as the Phillies made their big entrance onto the field during pregame festivities surrounding Opening Day presented by Nemours Children’s Health on Monday Highlights included surprise ceremonial first-pitches by Super Bowl-winning Eagles Saquon Barkley and Brandon Graham (with the Vince Lombardi trophy on-hand) all before a sell-out crowd at Citizens Bank Park Also featured are terrific in-game photos from the Phillies 6-1 victory over the Colorado Rockies